Unichem Laboratories Share Price

Pharmaceuticals company Unichem Laboratories announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from Operations: The consolidated revenue from operations for Q4FY26 stood at Rs 575.12 crore, registering a growth of 10.35% QoQ compared to Rs 521.17 crore in Q3FY26, but witnessed a decline of 2.05% YoY against Rs 587.18 crore in Q4FY25. For FY26, revenue increased by 4.31% YoY to Rs 2,201.85 crore from Rs 2,110.97 crore in FY25. Total Income: Total income reported in Q4FY26 was Rs 598.59 crore, up by 12.31% QoQ (vs Rs 532.97 crore in Q3FY26) and marginally up by 0.36% YoY (vs Rs 596.43 crore in Q4FY25). For FY26, total income stood at Rs 2,264.91 crore, an increase of 5.53% YoY compared to Rs 2,146.29 crore in FY25. Profit Before Tax (PBT): PBT for Q4FY26 was Rs 18.79 crore, showing a significant drop of 93.60% QoQ (vs Rs 293.43 crore in Q3FY26) and a decline of 67.49% YoY (vs Rs 57.80 crore in Q4FY25). However, For FY26, PBT surged by 89.13% YoY to Rs 292.38 crore compared to Rs 154.59 crore in FY25. Profit After Tax (PAT): The net profit for Q4FY26 stood at Rs 10.91 crore, dropping by 95.87% QoQ (vs Rs 264.29 crore in Q3FY26) and falling 79.40% YoY (vs Rs 52.97 crore in Q4FY25). For FY26, PAT jumped by 83.86% YoY to Rs 252.84 crore against Rs 137.52 crore in FY25. Total Comprehensive Income: The company posted a total comprehensive income of Rs 20.07 crore in Q4FY26 (vs Rs 262.22 crore in Q3FY26 and Rs 46.70 crore in Q4FY25). For FY26, it stood at Rs 264.83 crore, compared to Rs 130.55 crore in FY25. Standalone Financial Highlights: Revenue from Operations: Standalone revenue for Q4FY26 was Rs 356.24 crore, which is a QoQ increase of 13.13% (vs Rs 314.90 crore in Q3FY26), but a YoY decline of 22.76% (vs Rs 461.24 crore in Q4FY25). For FY26, revenue stood at Rs 1,412.29 crore, representing an 18.63% YoY decline from Rs 1,735.70 crore in FY25. Total Income: Standalone total income in Q4FY26 came in at Rs 378.46 crore, growing 14.71% QoQ (vs Rs 329.93 crore in Q3FY26) and dropping 19.01% YoY (vs Rs 467.29 crore in Q4FY25). For FY26, total income fell by 16.96% YoY to Rs 1,475.19 crore (vs Rs 1,776.53 crore in FY25). Profit / (Loss) Before Tax (PBT): The company reported a standalone loss before tax of Rs 10.71 crore in Q4FY26, turning negative from a profit of Rs 259.82 crore in Q3FY26 and Rs 56.03 crore in Q4FY25. For FY26, PBT grew by 14.63% YoY to Rs 209.41 crore, up from Rs 182.68 crore in FY25. Profit / (Loss) After Tax (PAT): The company incurred a standalone net loss of Rs 15.39 crore in Q4FY26, compared to a net profit of Rs 216.11 crore in Q3FY26 and a profit of Rs 51.22 crore in Q4FY25. For FY26, PAT was Rs 158.94 crore, reflecting a minor decline of 2.47% YoY compared to Rs 162.96 crore in FY25. Total Comprehensive Income: Standalone total comprehensive loss for Q4FY26 was Rs 12.74 crore. For FY26, total comprehensive income increased slightly to Rs 166.54 crore compared to Rs 163.06 crore in FY25. Business Highlights & Segment-wise Performance: Segment Performance: The company operates entirely under a single reportable operating segment, which is 'Pharmaceuticals'. Corporate Appointments: Mr. Pabitrakumar Bhattacharyya was re-appointed and redesignated from 'Managing Director' to 'Managing Director & Chief Executive Officer' for a further period of three years, starting from 10th August 2026 up to 9th August 2029. Result PDF

• Trendlyne
• 1 week 6 days ago

Pharmaceuticals company Unichem Laboratories announced Q3FY26 results Revenue: Rs 521.17 crore against Rs 533.09 crore during Q3FY25, change -2%. PBT: Rs 293.43 crore against Rs 61.85 crore during Q3FY25, change 374%. PAT: Rs 264.29 crore against Rs 57.85 crore during Q3FY25, change 357%. EPS: Rs 37.54 for Q3FY26. Result PDF

• Trendlyne
• 3 months 3 weeks ago

Unichem Laboratories' stock fell 5 per cent after a demand notice from the European Commission for a fine of Euro 19.49 million

• Business Standard
• 8 months 2 weeks ago